Table 3.
Univariate and multivariate Cox-regression analysis of clinical factors associated with the occurrence of KDIGO 3 acute kidney injury
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR (95% CI) | P-value | aOR (95% CI)a | P-value | |
| Age | 0.99 (0.97–1.01) | 0.236 | 0.99 (0.96–1.02) | 0.463 |
| Sex | ||||
| Female | 1.00 | – | 1.00 | – |
| Male | 0.72 (0.38–1.36) | 0.312 | 0.70 (0.34–1.46) | 0.346 |
| Baseline eGFR < 30 | 1.65 (0.69–3.91) | 0.260 | 1.41 (0.48–4.14) | 0.536 |
| Diabetes | 0.93 (0.47–1.82) | 0.824 | 1.16 (0.56–2.41) | 0.681 |
| APACHII ≥ 25 | 0.64 (0.34–1.20) | 0.162 | 0.53 (0.24–1.17) | 0.118 |
| Albumin ≤ 3 g/dL | 0.81 (0.42–1.54) | 0.522 | 0.66 (0.34–1.28) | 0.221 |
| CRAB | 0.61 (0.29–1.29) | 0.197 | 0.53 (0.24–1.17) | 0.118 |
| Aminoglycoside | 1.01 (0.40–2.58) | 0.982 | 0.99 (0.34–2.86) | 0.979 |
| Vancomycin | 1.99 (0.92–4.3) | 0.082 | 1.59 (0.65–3.89) | 0.310 |
| Intravenous contrast | 1.07 (0.51–2.23) | 0.865 | 0.89 (0.37–2.12) | 0.785 |
| Septic shockb | 2.79 (1.51–5.16) | 0.001 | 2.17 (1.10–4.26) | 0.025 |
| Daily colistin > 10 MIU | 1.75 (0.94–3.26) | 0.077 | 1.32 (0.61–2.83) | 0.482 |
| Colistin treatment duration | 0.98 (0.92–1.03) | 0.411 | 0.99 (0.93–1.04) | 0.617 |
| Inappropriate colistin dosage | 2.29 (1.09–4.80) | 0.028 | 2.52 (1.00–6.33) | 0.049 |
| Colistin formulation | ||||
| Locolin® | 1.00 | – | 1.00 | – |
| Colimycin® | 0.42 (0.22–0.82) | 0.011 | 0.37 (0.18–0.77) | 0.008 |
aAdjusted odds ratio (aOR) and 95%CI were derived from cox regression analysis
bPresent on the day of sample collection